We are live on ! Find out more
GLRA

Gerald L. Ray & Associates Portfolio holdings

AUM $802M
1-Year Est. Return 21.01%
This Fund
S&P 500
This Quarter Est. Return
+3.98%
1 Year Est. Return
+21.01%
3 Year Est. Return
+38.23%
5 Year Est. Return
10 Year Est. Return
AUM
$802M
AUM Growth
+$26.7M
Cap. Flow
+$2.39M
Cap. Flow %
0.3%
Top 10 Hldgs %
28.66%
Holding
337
New
15
Increased
53
Reduced
138
Closed
9

Sector Composition

Rank Sector Weight
1 Healthcare 22.98%
2 Industrials 15.02%
3 Technology 10.52%
4 Financials 9.61%
5 Consumer Staples 9.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ERIC icon
326
Ericsson
ERIC
$31.6B
$58K 0.01%
10,090
CRMD icon
327
CorMedix
CRMD
$643M
$30K ﹤0.01%
11,400
-14,000
-55% -$29K
WIN
328
DELISTED
Windstream Holdings Inc
WIN
$27K ﹤0.01%
3,031
BKNG icon
329
Booking.com
BKNG
$139B
-2,850
Closed -$213K
NGG icon
330
National Grid
NGG
$81.7B
-4,174
Closed -$232K
PNR icon
331
Pentair
PNR
$10B
-5,252
Closed -$235K
SYF icon
332
Synchrony
SYF
$24.7B
-10,200
Closed -$304K
TCRT icon
333
Alaunos Therapeutics
TCRT
$4.96M
-146
Closed -$136K
TWLO icon
334
Twilio
TWLO
$31.2B
-25,100
Closed -$731K
ICPT
335
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
-14,550
Closed -$1.76M
PETX
336
DELISTED
Aratana Therapeutics, Inc.
PETX
-24,100
Closed -$174K
DD
337
DELISTED
Du Pont De Nemours E I
DD
-108,016
Closed -$8.72M

Similar funds

Gerald L. Ray & Associates's Q3 2017 Portfolio in Review

As of Q3 2017, Gerald L. Ray & Associates held 337 positions worth $802M, up 3.4% from $775M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Gerald L. Ray & Associates's Q3 2017 filing shows 15 new, 53 increased, 138 reduced and 9 closed positions. Its largest new stake was Clovis Oncology, Inc.: 42,630 shares worth $3.51M. The largest sale was Du Pont De Nemours E I, an estimated $8.72M.

By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 22% a quarter earlier, followed by Industrials and Technology.

  • Gerald L. Ray & Associates's largest Q3 2017 buy was Clovis Oncology, Inc.: 42,630 shares worth $3.51M.
  • Gerald L. Ray & Associates added most to DuPont de Nemours in Q3 2017, an estimated $9.04M increase.
  • Gerald L. Ray & Associates's biggest Q3 2017 reduction was Under Armour, cutting an estimated $709K.
  • Gerald L. Ray & Associates fully exited Du Pont De Nemours E I in Q3 2017, selling an estimated $8.72M.
  • Gerald L. Ray & Associates's ten largest holdings make up 29% of its $802M portfolio in Q3 2017.
  • Gerald L. Ray & Associates opened 15 new positions and closed 9 in Q3 2017.
  • Gerald L. Ray & Associates's portfolio value rose 3.4% quarter-over-quarter to $802M.

Based on Gerald L. Ray & Associates's 13F filing for Q3 2017, filed 31 Oct 2017.